Isotiorga

Isotretinoin, the active ingredient in Isotiorga, is a retinoid presented as a tablet for oral use. It treats severe nodular acne and acne vulgaris in patients who have not responded to other therapies.

GNH USA supplies Isotiorga as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isotiorga, a retinoid, is used to manage severe forms of acne by targeting the underlying pathophysiology.

Severe nodular acne: reduces inflammatory nodules and prevents new lesion formation. Acne vulgaris: decreases sebum production and improves skin clarity. Acne conglobata: helps clear extensive, deep‑seated lesions in refractory cases.

Isotiorga may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin and mucous membranes - Cheilitis (cracked lips) - Xerosis (dry eyes) - Photosensitivity - Elevated triglycerides - Headache

Serious or Rare Side Effects: - Severe depression or mood changes - Inflammatory bowel disease - Hepatotoxicity (elevated liver enzymes) - Severe hypertriglyceridemia - Teratogenicity (birth defects) - Pseudotumor cerebri (increased intracranial pressure)

Before initiating therapy, clinicians should evaluate specific safety considerations.

Pregnancy: Contraindicated; category X due to high teratogenic risk. Liver function: Monitor hepatic enzymes regularly. Lipid profile: Check triglycerides and cholesterol before and during treatment. Vitamin A supplements: Avoid concurrent use to prevent excess toxicity. Contraception: Ensure effective birth control throughout therapy and for one month after discontinuation. Store at below 25°C: keep in the original pack, protect from moisture.

Isotiorga can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Tetracyclines: increased risk of pseudotumor cerebri. - Vitamin A supplements: additive retinoid toxicity. - Systemic corticosteroids: may diminish isotretinoin efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive effectiveness. - Anticoagulants (e.g., warfarin): altered INR values. - Statins: heightened risk of myopathy when triglycerides rise. - Azithromycin: enhanced photosensitivity.